Yuji Takeda, Tomoyuki Kato, Saima Sabrina, Sei Naito, Hiromi Ito, Naoto Emi, Yuya Kuboki, Yuki Takai, Hiroki Fukuhara, Masaki Ushijima, et al. Intracellular Major Histocompatibility Complex Class II and C-X-C Motif Chemokine Ligand 10-Expressing Neutrophils Indicate the State of Anti-Tumor Activity Induced by Bacillus Calmette-Guérin. Biomedicines. 2023. 11. 11
Shigemitsu Horie, Sei Naito, Shingo Hatakeyama, Shuya Kandori, Kazuyuki Numakura, Renpei Kato, Tomoyuki Koguchi, Shingo Myoen, Yoshihide Kawasaki, Akihiro Ito, et al. Preoperative prognostic model for localized and locally advanced renal cell carcinoma: Michinoku Japan Urological Cancer Study Group. International journal of clinical oncology. 2023
Renpei Kato, Sei Naito, Kazuyuki Numakura, Shingo Hatakeyama, Tomoyuki Koguchi, Takahiro Kojima, Yoshihide Kawasaki, Shuya Kandori, Sadafumi Kawamura, Yoichi Arai, et al. Correction to: Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era - a multi-institutional retrospective study. International journal of clinical oncology. 2023. 28. 5. 726-727
Hayato Nishida, Satoshi Takai, Hiromi Ito, Hiroki Fukuhara, Takaaki Nawano, Takafumi Narisawa, Hidenori Kanno, Mayu Yagi, Atsushi Yamagishi, Toshihiko Sakurai, et al. Anti-human leukocyte antigen and anti-ABO antibodies after SARS-CoV-2 mRNA vaccination in kidney transplant recipients. Clinical transplantation. 2023. e14952
Takafumi Narisawa, Sei Naito, Hiromi Ito, Osamu Ichiyanagi, Toshihiko Sakurai, Tomoyuki Kato, Norihiko Tsuchiya. Fibroblast growth factor receptor type 4 as a potential therapeutic target in clear cell renal cell carcinoma. BMC cancer. 2023. 23. 1. 170-170